The Zacks Analyst Blog Highlights: Ford Motor, General Motors, Toyota Motor,
Honda Motor and Sanofi
CHICAGO, April 2, 2013
CHICAGO, April 2, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Ford Motor Co. (NYSE:F), General
Motors Co. (NYSE:GM), Toyota Motor Corp. (NYSE:TM), Honda Motor Co. (NYSE:HMC)
and Sanofi (NYSE:SNY).
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
Ford Sees Lower Margins in North America
Ford Motor Co. (NYSE:F) revealed that its operating margins from North
American operations will come down to 10.0% in 2013 from 10.4% last year as it
expects the lion's share of sales to generate from less-profitable small cars
rather than high-margin trucks.
Ford also expects increased costs associated with higher volumes to affect
margins growth. However, the automaker is banking on an improving U.S. auto
market, higher market share and increased prices to boost its revenues.
In February this year, Ford topped all automakers in terms of year-over-year
sales growth. The company's sales rose 9.3% to 195,310 vehicles, driven by
impressive sales of its Escape SUV and Fusion sedan. Escape sales soared 29%
while Fusion sales surged 28% during the month. Together, the vehicles
contributed more than a quarter of the company's monthly sales.
General Motors Co. (NYSE:GM) posted a 7.2% rise in sales to 224,314 vehicles
in February, driven by strong Chevrolet Silverado and GMC Sierra pickup trucks
sales like January. Sales of Chevrolet Silverado leaped 29% while GMC Sierra
sales jumped 25% during the month.
Japanese automaker Toyota Motor Corp. (NYSE:TM) saw a disappointing 4.3% rise
in sales to 166,377 vehicles compared to its earlier performance as its
popular car sales dipped 3% and its less popular sport utility vehicles and
truck sales rose 16% during the month. Despite higher gas prices, sales of its
Prius hybrid went down 13.5%.
Another Japanese automaker, Honda Motor Co. (NYSE:HMC) recorded a 2.0% drop in
sales to 107,987 vehicles as steep declines of its CR-V crossover and Civic
small car sales offset its strong 35% rise in new Accord sales. The company
also attributed heavy winter storms in the Northeast for the decline in sales.
Ford, a Zacks Rank #3 (Hold) stock, posted a robust 55.0% rise in earnings per
share to 31 cents in the fourth quarter of 2012 from 20 cents in the same
quarter of 2011 (all excluding special items). With this, the company has
beaten the Zacks Consensus Estimate of 26 cents
Ford's fourth-quarter pre-tax profit of $1.7 billion was the highest in a
decade. Meanwhile, net profit surged 55.7% to $1.2 billion from $797 million a
year ago. Thanks to the impressive North American results and, to some extent,
solid improvements in Asia-Pacific-Africa operations.
Ford's market share in 2012 was 15.2% in the U.S., 7.9% in Europe and 3.2% in
China. In 2013, Ford expects market share in the U.S. to be higher than 2012,
Europe to be almost the same as in 2012, and China to be higher than 2012.
During the year, Ford anticipates total company pre-tax operating profit to be
the same as in 2012. Ford Credit is expected to report flat pre-tax operating
profit compared with 2012.
Sanofi Invests in Emerging Markets
Sanofi (NYSE:SNY) recently announced that it has started constructing a new
manufacturing facility in the Saigon High Tech Park – Ho Chi Minh City,
Vietnam. Sanofi plans to invest approximately $75 million on this new plant.
The new plant is expected to be fully operational by the end of 2015.
The manufacturing facility is expected to produce pharmaceuticals and consumer
healthcare products with an initial capacity of 90 million units per year,
which is expandable up to 150 million units.
We believe that the manufacturing facility will help Sanofi to meet the demand
in Vietnam and Association of South East Asian Nations (ASEAN) markets.
The signing of the deal comes close on the heels of Sanofi's collaboration
with a French biopharmaceutical company, Transgene, for the production of
immunotherapy products and creating of an industrial platform for the same.
The platform will include Transgene's candidates.
Sanofi and Transgene will invest €10 million in the platform, which will be
located at the Genzyme Polyclonals site at Lyon, Gerland. The platform will be
solely owned by Sanofi.
Construction, qualification and validation of the manufacturing facility are
expected to commence in the third quarter of 2013. Sanofi expects the first
batch of commercial grade drugs to be available in 2015.
We note that Sanofi is looking to combat the threat of genericization hanging
over many of its drugs by signing deals/making acquisitions. The company's
focus on the high potential emerging markets is also impressive.
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.